Cargando…

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC

Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), acquired drug resistance to targeted therapy remains a major obstacle. Epithelial-mesenchymal transition (EMT) has been identified as a key resistance mechanism in NSCLC. Here, we investigated the mechanistic role of key...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gohlke, Linus, Alahdab, Ahmad, Oberhofer, Angela, Worf, Karolina, Holdenrieder, Stefan, Michaelis, Martin, Cinatl, Jindrich, Ritter, Christoph A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573279/ https://www.ncbi.nlm.nih.gov/pubmed/37834189 http://dx.doi.org/10.3390/ijms241914742

Ejemplares similares

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
por: Saafan, Hisham, et al.
Publicado: (2021)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
por: Perez-Oquendo, Mabel, et al.
Publicado: (2023)

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
por: Sánchez-Tilló, Ester, et al.
Publicado: (2023)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
por: Farhan, Mohd, et al.
Publicado: (2019)

Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT
por: Zhong, Chunlian, et al.
Publicado: (2020)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells
por: Vad-Nielsen, Johan, et al.
Publicado: (2023)

Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A
por: Michaelis, Martin, et al.
Publicado: (2014)

Investigation of the influence of EPs(®) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
por: Michaelis, Martin, et al.
Publicado: (2011)

Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Author Correction: Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT
por: Zhong, Chunlian, et al.
Publicado: (2020)

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
por: Li, Ling, et al.
Publicado: (2017)

A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer
por: Preca, Bogdan-Tiberius, et al.
Publicado: (2017)

Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb
por: Egger, Jacklynn V., et al.
Publicado: (2016)

ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC
por: Lazarova, Darina, et al.
Publicado: (2017)

Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer
por: Wu, Hua-Tao, et al.
Publicado: (2020)

Zeb2 directs EMT-like processes that underlies the glial response to injury
por: Vivinetto, Ana L., et al.
Publicado: (2021)

The Status of EGFR Modulates the Effect of miRNA-200c on ZEB1 Expression and Cell Migration in Glioblastoma Cells
por: Muñoz-Hidalgo, Lisandra, et al.
Publicado: (2020)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
por: Zhu, Jing, et al.
Publicado: (2021)

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs
por: Ahmad, Aamir, et al.
Publicado: (2013)

TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation via UPP
por: Shang, Rongxin, et al.
Publicado: (2023)

Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity
por: Wang, Jueqiong, et al.
Publicado: (2021)

ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1
por: Liu, D, et al.
Publicado: (2018)

EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells
por: Lindner, Pablo, et al.
Publicado: (2020)

Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells
por: Ichikawa, Mai Koizumi, et al.
Publicado: (2022)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)

Development of antiviral therapy for severe acute respiratory syndrome
por: Cinatl, Jindrich, et al.
Publicado: (2005)

miR-655 Is an EMT-Suppressive MicroRNA Targeting ZEB1 and TGFBR2
por: Harazono, Yosuke, et al.
Publicado: (2013)

The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors
por: Mock, Kerstin, et al.
Publicado: (2015)

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
por: Rae, Sophie, et al.
Publicado: (2022)

Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
por: He, Zhiyong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gka9pucl4e0n5tn6gokch5aks2